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Altered ceramide and sphingosine expression during the induction
phase of ischemic acute renal failure. Recent evidence indicates that a
"sphingomyelin signaling pathway" exists: in response to heterogeneous
influences, sphingomyelin is hydrolyzed, liberating ceramidc, and subse-
quently its sphingoid base, sphingosine. Ceramide and sphingosine can
influence diverse cellular processes, including cell differentiation, prolif-
eration, protein trafficking, and apoptosis. Each of these processes have
important implications for post-ischemic acute renal failure (ARF).
However, sphingosine and ceramide expression during the induction of
ischemic/reperfusion injury have not been previously assessed. To this end,
CD-I mice were subjected to 45 minutes of unilateral renal ischemia
reperfusion, followed by cortical sphingosine, ceramide, and sphingomy-
elm assessments. Contralateral kidneys served as controls. Ischemia
caused —50% sphingosine and ceramide decrements. During reperfusion,
sphingosine rebounded to normal values. Conversely, ceramide rose to,
and was maintained at, supranormal levels (—175% of controls). Subse-
quent studies performed with hypoxic or oxygenated isolated proximal
tubules suggested that these changes: (1) had a multifactorial basis; (2)
were partially simulated by enhanced PLA2 activity; (3) and were disso-
ciated from alterations in net sphingomyelin content. To assess the
potential pathogenic relevance of the documented ceramide increments,
cultured human proximal tubule (HK-2) cells were subjected to ATP
depletion/Ca2 ionophore- or PLA2-induced attack with or without
exogenous C2 ceramide loading. Ceramide worsened both forms of injury
without exerting an independent lethal effect. Conversely, ceramide
markedly attenuated arachidonic acid cytotoxicity. This occurred without
any decrease in arachidonate uptake, suggesting a direct cytoprotective
effect. In conclusion: (1) sphingosine and ceramide fluxes are hallmarks of
early ischemic/reperfusion injury; (2) these changes occur via divergent
metabolic pathways; and (3) that ceramide increments can affect divergent
injury pathways, and that sphingosine and ceramide have potent cell
signaling effects, suggest that the currently documented sphingosine/
ceramide fluxes could have important implications for the induction phase
and evolution of post-ischemic ARF.
Sphingomyelin traditionally has been viewed simply as a struc-
tural component of plasma membranes, comprising approxi-
mately 5 to 15% of total phospholipid content [1]. However,
during the past 10 years it has become increasingly clear that
sphingomyelin is not just a membrane "building block," since it
also serves as a source of cell signaling molecules [1—5]. Under a
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variety of influences (such as, TNF a, arachidonic acid, interleu-
kin-i, y interferon, complement, vitamin D, corticosteroids),
sphingomyelin is hydrolyzed by plasma membrane or lysosomal
sphingomyelinases, resulting in ceramide release [1—5]. Ceramide
can then be deacylated by eeramidase(s), liberating its sphingoid
base, sphingosine. In turn, sphingosine can undergo phosphory-
lation via a sphingosine kinase, sphingosine-1-phosphate forma-
tion being the result. A burgeoning experimental literature indi-
cates that each of these sphingomyelin derivatives can have
potent, and sometimes divergent, effects on cellular homeostasis.
For example, the addition of sphingolipid derivatives to cultured
cells may alter cell proliferation and differentiation [6—9], inhibit
protein trafficking [10—13], modulate cell adhesion/motility [14,
15], and initiate apoptosis (such as, [16—22]). Since diverse
biological agents seemingly mediate their effects through sphin-
gomyelin hydrolysis, it has been suggested that a sphingomyelin
"signaling pathway" exists [1—5]. This may be analogous to
PLA2-initiated cell signaling through glycerolipid hydrolysis prod-
ucts (such as, via diaeylglycerol, inositol triphosphate, and eico-
sanoids). Indeed, it has been postulated that the glycerolipid- and
sphingolipid signaling pathways may have interactive, and poten-
tially counter-regulatory, effects [4].
This laboratory recently demonstrated that exogenous sphingo-
myelin derivatives can have a marked impact on proximal tubular
cell integrity, as assessed with a cell culture system [23]. For
example, when sphingosine, sphingosine-1-phosphate, or cell
membrane permeable ceramides were added to HK-2 cells (a
proximal tubular cell line from an adult human kidney), a dose
dependent loss of viability resulted [23]. Conversely, if the cells
were exposed to subtoxic doses of sphingosine for —18 hours,
they became relatively resistant to superimposed ATP deple-
tion/Ca2 ionophore-induced attack (that is, a "cytoresistant
state" emerged). Neither ceramide nor sphingosine-1-phos-
phate was able to reproduce this sphingosine-initiated cytore-
sistance. This suggested that it was a compound specific result,
and not just a downstream consequence of a cellular "stress
response" [24, 25].
Given these observations, we previously speculated that if
perturbations in the sphingomyelin signaling pathway were to
develop during renal injury, they could potentially impact on
tubular cell integrity [23]. However, no evidence existed at that
time to indicate that alterations in sphingosine or ceramide
expression do, in fact, exist during the evolution of acute renal
tubular damage. The present study was undertaken to test for this
possibility. To this end, mouse kidneys or isolated proximal
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tubular segments (PTS) were subjected to in vivo or ex vivo injury
and then sphingosine, ceramide, and sphingomyelin concentra-
tions were determined. Since these studies indicated that alter-
ations in sphingosine and ceramide expression do develop during
acute tubular injury, additional studies were undertaken to assess
some possible reasons for these changes and to determine their
potential impact on the evolution of acute tubular damage. Since
interactions between glycerophospholipid and sphingomyelin by-
products have been suggested [4], the impact of ceramide on the
expression of PLA2 and arachidonic acid mediated cytotoxicity
was also addressed.
METHODS
In vivo ischemic/reperfusion injury protocol
Male CD-i mice (25 to 35 grams; Charles River Laboratories,
Wilmington, MA, USA) maintained under standard vivarium
conditions were used for all whole kidney and isolated proximal
tubule segment (PTS) experiments. They were injected with
pentobarbital (—--2 mg i.p.), and after the development of deep
anesthesia they underwent a midline abdominal incision to expose
both renal pedicles. During this procedure, normothermia was
maintained by placing the animals in a 37°C warm room. Three
sets of experiments were performed, as follows:
In vivo ischemia. Ten mice were subjected to total left renal
ischemia by passing a silk ligature around the left renal pedicle
and then inducing total vascular occlusion. After a 45-minute
ischemic period, both kidneys were resected. The right kidney
served as a control. Once resected, each kidney was cooled to 4°C,
cortical tissues samples were obtained with a razor blade, the
tissues were snap frozen in liquid N2, and then they were stored
frozen until sphingosine analysis (see below).
Ex vivo ischemia. Pilot data indicated that intrarenal heme
trapping, a result of renal pedicle occlusion, caused an artifactual
lowering of tissue ceramide concentrations. Therefore, it was
necessary to induce whole kidney ischemia while avoiding this
artifact. To this end, four mice were anesthetized and bilateral
nephrectomy was performed (allowing for blood efflux). The right
(control) kidney was immediately cooled, and cortical tissue
samples were snap frozen in liquid N2 and stored frozen until
ceramide assay (see below). The left kidney was wrapped in a
warm saline soaked gauze and then it was subjected to 45 minutes
of ex vivo ischemia by placing it in a 37°C warm room. At the
completion of this ex vivo ischemic period, it was frozen as above
and stored until ceramide assay.
In vivo ischemia/reperfusion. Twelve mice were anesthetized and
subjected to left renal pedicle occlusion, performed with a 1 cm
nontraumatic vascular clamp. After completing 45 minutes of
ischemia, the clamp was removed and a 30-minute reperfusion
period was permitted. At its completion, both the post-ischemic
kidney and the contralateral (control) kidney were resected and
frozen for subsequent assay. Eight of the paired kidneys were used
for ceramide determination. The remaining four pairs were
assayed for sphingosine.
Since the above experiments detected significant ceramide
increments at 30 minutes of reperfusion, four additional mice
were subjected to 45 minutes of unilateral ischemia plus a longer
reperfusion period (1 hr). This was done to ascertain whether the
post-ischemic ceramide increases were merely transient or rela-
tively sustained in duration.
Hypoxic injury in isolated proximal tubular segments (PTS)
Given the heterogeneity of cell types in cortical tissues, an in
vitro cell injury model was employed to help substantiate that
oxygen deprivation injury does, in fact, cause alterations in
proximal tubular sphingosine and ceramide content. To this end,
proximal tubular segments (PTS) were harvested from normal
mouse kidneys by a previously described technique [26]. In brief,
the kidneys were resected, cooled, the cortices dissected and finely
minced, and then the pieces were subjected to 30 minutes of
collagenase digestion at pH 6.5. The digest was passed through a
stainless steel sieve, the recovered material was centrifuged,
washed, and subjected to centrifugation through 32% Percoll. The
viable PTS, recovered in the pellet, were washed twice and
re-suspended in an experimentation buffer (in mmol/liter: NaCI,
100; KCI, 2.1; NaHCO1, 25; KH2PO4, 2.4; MgSO4, 1.2; MgCI2,
1.2; CaC12, 1.2; glucose, 5; alanine, 1; Na lactate, 4; 10 Na
butyrate; dextran, 0.6%; gassed with 95% 02/5% C02; pH 7.4).
The preparations were re-warmed to 37°C over 15 minutes, they
were divided into two 2 ml aliquots, and each aliquot was placed
into 25 ml Erlenmeyer flasks maintained within a shaking 37°C
water bath. One PTS aliquot was subjected to 20 minutes of
hypoxia (gassing with 95% N2/5% C02); the second PTS aliquot
underwent simultaneous oxygenated incubation (95% 02/5%
C02). At the completion of these treatments, the extent of lethal
cell injury was determined by calculating % lactate dehydrogenase
(LDH) release [26]. The samples were then assayed for either
sphingosine or ceramide concentrations (N = 8 and N = 5 control
and hypoxic pairs for sphingosine and ceramide, respectively).
Combined in vivo/in vitro myohemoglobinuric injury protocol
The following experiment was undertaken to ascertain whether
alterations in sphingosine/ceramide expression occur during the
evolution of nephrotoxie, as well as ischemic tubular injury. To
this end, a combined in vivo/in vitro model of myohemoglobinuric
tubular damage was used, as previously described [27, 28]. In
brief, 11 mice were anesthetized with pentobarbital and subjected
to intramuscular glycerol injection (8.5 ml/kg of 50% glycerol; in
2 divided doses into the upper hind limbs). The mice were placed
in a 37°C warm room to maintain body temperature. After one
hour (sufficient time to permit myohemoglobin tubular uptake),
PTS were isolated, as noted above. A baseline % LDH release was
obtained and then the PTS were incubated for one hour under
oxygenated conditions (allowing for the in vitro expression of
myohemoglobin-induced injury [27, 28]). After this period, %
LDH release was determined as a marker of lethal cell injury.
Then, the PTS were immediately extracted and analyzed for either
sphingosine (N 7) or ceramide content (N 4). PTS harvested
from normal mice and subjected to 60 minutes of oxygenated
incubation were used to establish normal sphingosine and cer-
amide concentrations for each of the assays (N = 4 for each).
Potential impact of PLA2 activity on sphingosine and ceramide
concentrations
The following experiment was undertaken to ascertain whether
increased PLA2 activity, a consequence of acute ischemic tubular
damage [29—31], might be mechanistically linked to altered sphin-
gosine/ceramide expression. To this end, 13 sets of PTS were
prepared from normal mice and each preparation was divided into
62 Zager et a!: Ceramideisphingosine expression during ischemia
two aliquots: control oxygenated incubation or oxygenated incu-
bation in the presence of exogenous PLA2 (5 U/mI; from porcine
pancreas; P 6534; Sigma Chemicals, St. Louis, MO, USA). After
completing the 20-minute oxygenated incubations, the % LDH
release was determined. The samples were then immediately
extracted and analyzed for either sphingosine or ceramide (N = 8
and N = 5 paired determinations, respectively).
The above experiment indicated that PLA2 caused a marked
reduction in sphingosine concentrations without significantly al-
tering ceramide levels. The following experiment assessed
whether PLA2 caused this sphingosine lowering by enhancing its
flux through its two known major metabolic pathways: (1) acyla-
tion via ceramide synthase; or (2) phosphorylation via sphingosine
kinase. To achieve this end, the ability of a ceramide synthase
inhibitor (fumonisin Bi; FBi; Sigma) [21, 32—34] or a sphingosine
kinase inhibitor (dimethylsphingosine; DMS; Biomol, Plymouth
Meeting, PA, USA) [35] to block the PLA2 initiated sphingosine
depressions was assessed. Six PTS preparations were used to
create the following experimental treatments: (1, 2) oxygenated
incubation under control conditions 5 U/mI PLA2; (3, 4)
oxygenated incubation with 25 LM fumonisin Bi PLA2; and (5,
6) oxygenated incubation with 5 xivi dimethyisphingosine PLA2.
After completing the 20 minute incubations under these condi-
tions, an aliquot was removed for LDH assay and the rest of the
sample was used for the sphingosine assay.
Ceramide assay
Ceramide concentrations in renal cortex or proximal tubules
were determined enzymatically by measuring the formation of
ceramide-1-32P in the presence of [y-32Pj ATP under the influ-
ence of bacterial diacylglycerol (DG) kinase [36, 371. Since this
enzyme phosphorylates ceramide, and not just DG, the amount of
ceramide-1-32P formation serves as a quantitative index of cer-
amide concentrations. The assay of Younes et al was used [37]. In
brief, samples of renal cortex (50 mg) were homogenized in 4
volumes of phosphate buffered saline. In the case of PTS, an
aliquot equivalent to 3 to 6 mglml of PTS protein was centrifuged
and the pellet was used for assay. Lipids from the samples were
extracted in chloroform:methanol according to the method of
Bligh and Dyer [38]. The chloroform phase of each was dried
under N2. Samples of each (1/10th of the cortical extract; 1/5th of
the PTS extract) were solubilized by sonication in 20 xl of 7.5%
n-octyl j3-D-glucopyranoside, 5 mvt cardiolipin, and 1 mrvi dieth-
ylene triamine penta-acidic acid. Each sample was added to a
reaction buffer (20 jxl; 250 ifiM Tris-HC1, 500 mrvi NaCI, 10 mM
EGTA, 25 mrvt MgCI2, pH 7.0). Next, 6 d of bacterial DG kinase,
as supplied by the manufacturer (Calbiochem, La Jolla, CA, USA;
6.3 units per ml) was added. The reaction was started by adding 20
xl of 10 ms'i ATP (unlabeled ATP + labeled ATP: [y-32P] ATP,
2.5 mCi/mi; in 20 mrvi Tris-HCI, 10 mivi DTT, 1.5 M NaCI, 250 mM
sucrose, 15% glycerol, pH 7.4). After incubating at 22°C for 40
minutes (the reaction was shown to he linear for at least 40 mm
with the amount of employed lipid), the reaction was stopped by
extracting the lipids with 1 ml chloroform:methanol:HC1 (100:
100:1) + 30 p1100mM EDTA + 170 pJ of buffered saline (135 mM
NaCl, 1.5 mrvi CaCI2, 0.5 mrt MgCl2, 5.6 mM glucose, 10 mM
HEPES, pH 7.2). The lower organic phase was recovered,
washed x 3 with the buffered saline and dried under N2. The
32P-labeled ceramide was separated from the rest of the lipids by
thin layer chromatography (TLC), using chloroform :acetone:
methanol:acetic acid:water (100:40:20:20:10) as solvent. The
plates were analyzed by autoradiography. The ceramide-1-32P
band was recovered by scraping and then counted in scintillation
fluid. The amount of ceramide was calculated from a standard
curve constructed with 0, 1.12, 2.24, 5.6, 8.4, 11.2, and 12.5 nmol
of type III ceramide (from bovine brain; Sigma Chemicals).
Sphingosine assay
Renal cortical tissues and PTS were assayed for sphingosine by
a modification of the HPLC technique of Merrill et al [391. In
brief, renal cortical samples were homogenized as noted above
and then these samples and the PTS samples were extracted by
the method of Bligh and Dyer [38]. The chloroform extract was
washed, dried and incubated at 37°C for one hour in 3 ml of 0.2
M NaOH in methanol at 37°C for one hour to cleave the
acyiglycerolipids. Then, 3 ml of chloroform and 3 ml of 1 M NaC1
was added and the free long chain bases were recovered in the
chloroform phase. The chloroform phase was washed with 5 ml of
a wash solution (3 ml chloroform: 48 ml methanol: 47 ml water)
and then the chloroform phase was dried. The long chained bases
were derivatized with o-phthalaldehyde (OPA) [39]. The derivat-
ized bases were quantitated by HPLC using a C18 column
(Ailtech Adsorbosphere OPA HR; 5 x, 150 X 4.6 mm; Ailtech
Corp., Deerfield, IL, USA) and a methanol-S m potassium
phosphate (pH 7.0) solvent system (82:18 vol:vol). Detection was
performed with a spectrofluorometer (Hewlett Packhard, Wil-
mington, DE, USA; excitation and emission wavelengths, 340 nm
and 455 nm, respectively). The values were calculated from a
standard curve constructed with 0, 10, 25, 50, 100, 200, 500 pmole
sphingosine standards (Biomol).
Sphingomyelin assay
The following experiments assessed the impact of the in vivo
ischemia/reperfusion injury protocol and the in vitro hypoxic
injury protocol on sphingomyelin content. Three mice were
subjected to unilateral renal ischemia (45 mm of left renal pedicle
occlusion) and 30 minutes of vascular reflow. Then the cortex of
the post-ischemic kidney and the contralateral control kidney
were isolated and stored frozen until assay. In other experiments,
four sets of PTS were prepared and each was divided into two
aliquots: oxygenation X 40 minutes or 20 minutes hypoxia + 20
minutes of reoxygenation, followed by assessment of LDH re-
lease. Lipids were extracted from kidney cortex ('—50 mg/wet wt)
or from pelleted PTS (2 to 6 mg PTS protein) by the method of
Bligh and Dyer [381. The lipid phase was dissolved in 2:1
chloroform:methanol (1 and 0.5 ml used for cortex and PTS,
respectively) and 90 1d were saved for phosphorus quantitation
[40]. The rest of the lipids were dried under N2 and resuspended
in 50 p1 of 2:1 chloroform:methanol. Lipid samples (10 to 15 pi)
were subjected to TLC using chloroform:methanol:acetic acid:
water (50:30:8:5) as the solvent. The sphingomyelin bands were
visualized with 0.03% primulin spray, scraped, and quantitated by
its phosphorus content [40].
Cell culture experiments
The overall goal of these experiments was to assess whether
ceramide accumulation (such as, during ischemia), can impact on
the evolution of renal tubular damage. Three questions were
addressed:
(1) Since ischeniic tubular injury is mediated, in part, by ATP
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depletion + Ca2 overload [30, 31], might increased cell ceramide
levels alter the extent of this form of tissue damage?
(2) Since PLA2 activation is a consequence of ischemic injury
[29], might increased ceramide levels alter PLA2 effects on
cellular integrity?
(3) Might ceramide accumulation potentially impact on "down-
stream" consequences of PLA2 activation (such as, altering cellu-
lar responses to arachidonic acid accumulation)?
These issues were addressed using cultured HK-2 cells, a
proximal tubular cell line derived from a normal human kidney
[41]. [Note: PTS were not used for these experiments because
their isolation causes membrane damage, arachidonic acid accu-
mulation, and potentially ceramide release, complicating data
interpretation.] The cells were maintained in keratinocyte serum
free medium (K-SFM; Gibco/BRL, Grand Island, NY, USA) to
which was added 1 mrvi glutamine, 5 ng/ml epidermal growth
factor, 40 xg/ml bovine pituitary extract, 25 U/mi penicillin, and
25 xg/ml streptomycin. Prior to experimentation, the cells, grown
in T 75 Costar flasks (Cambridge, MA, USA), were trypsinized
and transferred to 24-well Costar cluster plates. After an approx-
imate 18-hour recovery period, they were used for experimenta-
tion, as described below. Cell viability in each experiment was
assessed by determining LDH release [42]. Each experiment
represented an N  10, performed on at least three separate
occasions.
Does ceramide alter the expression of ATP depletion/Ca
ionophore-induced cell death?
Simultaneously cultured HK-2 cells were exposed to one of the
following conditions: (1) control culture conditions; (2) 25 xM C2
ceramide addition (a synthetic cell membrane permeable cer-
amide); or (3) C16 (relatively impermeant) ceramide. The cer-
amides (obtained from Biomol) were added in 0.125% ethanol.
After completing 10 minutes ceramide exposures, the cells in each
well were subjected to a combined ATP depletion/Ca2 overload
injury protocol (7.5 ILM antimycin + 20 mrvi 2-deoxyglucose + 10
p Ca ionophore A23187) [43]. One hr later, % LDH release
was determined. Co-incubated cells exposed to 25 LM C2 cer-
amide, 25 xM C16 ceramide, or to routine culture conditions (with
0.125% ethanol addition) and not challenged with ATP deple-
tion/Ca ionophore addition were used to establish independent
ceramide effects on cell viability.
Does ceramide alter the expression of exogenous PLA2 toxicity?
HK-2 cells were subjected to incubation under one of the
following conditions: (1) control conditions; (2) 25 IxM C2 cer-
amide addition; or (3) 25 jLM palmitic acid addition (as a lipid
control). After completing 10 minutes exposures, the cells were
challenged with 10 U/mi of exogenous PLA7. After completing
four hours incubations, % LDH release was determined. Con-
comitantly treated cells exposed to C2 ceramide or palmitic acid
but not to PLA2 served to establish independent effects of the test
agents.
Does ceramide alter arachidonic acid toxicity?
HK-2 cells were cultured under: (a) control conditions; (b) with
a toxic dose of arachidonic acid (50 xM, in 0.25% ethanol); (c)
with 25 LM C2 ceramide, followed 10 minutes later by 50 fLM
arachidonic acid addition; or (d) with 25 xM palmitic acid,
followed 10 minutes later by 50 LM arachidonic acid addition (the
palmitate serving as a lipid control). After completing two hours
arachidonic acid exposures, % LDH release was determined.
Co-incubated cells maintained under control conditions or with
two hours exposures to either 25 jIM C2 ceramide or 25 jIM
palmitic acid established independent effects of these test agents
on cell viability.
Potential determinants of ceramide's protective effect against
arachidonic acid toxicity
C2 ceramide was found to markedly mitigate arachidonic acid
toxicity. The following two experiments were undertaken to assess
potential determinants of this effect.
(a) Is cell ceramide uptake required for cytoprotection? C16
ceramide, unlike C2 ceramide, undergoes little cellular uptake.
Therefore, if cell ceramide uptake were critical to its ability to
blunt arachidonic acid toxicity, C2 ceramide should be much more
protective than C16 ceramide. C2 or C16 ceramide (25 jIM) was
added to HK-2 cells, followed 10 minutes later by the arachidonic
acid challenge. Two hours later, % LDH release was assessed.
The results were compared to co-incubated cells challenged only
with arachidonic acid addition.
(b) Does ceramide block arachidonic acid uptake by HK-2 cells?
The following experiment was undertaken to assess whether C2
ceramide blocks arachidonic acid toxicity by inhibiting its cellular
uptake. HK-2 cells were cultured either with 25 jIM C2 ceramide
or under control conditions (with 0.125% ethanol as the ceramide
vehicle). After 10 minutes exposures, 5 jIM unlabeled arachidonic
acid + 3H labeled arachidonic acid (5,6,7,8,11,12,14,15-
3H(N)C20:4; New England Nuclear, Wilmington, DE, USA;
—50,000 cpm) were added. After a 30 minute incubation to permit
3H arachidonic acid uptake, the media was removed, the cells
were washed with Hank's balanced salt solution (with Mg and
Ca), and then the cells were lysed with Triton bOX. The lysates
were then counted in a scintillation counter. Non specific (back-
ground) binding of 3H arachidonic acid was determined by
repeating the above experiments in culture plates treated exactly
as above but which contained no cells. This amount of background
(not affected by the presence of C2 ceramide) was then subtracted
from the values obtained with the lysed cultures.
Calculations and statistics
All values are presented as means I SEM. Statistical compar-
isons were performed by either paired or unpaired Student's
t-test, as appropriate. If multiple comparisons were made, the
Bonferroni correction was applied. Renal cortical ceramide and
sphingosinc concentrations were expressed per mg wet wt, per mg
dry weight, or as nmoles/total phospholipid phosphate. The
concentrations in PTS were either expressed per mg PTS protein
or as nmoles/total phospholipid phosphate.
RESULTS
Ceramide levels during oxygen deprivation injury
Whole kidney ischemia. As shown in Figure 1, left, eeramide
concentrations fell —33% during 45 minutes of ex vivo ischemia
(I), when factored by tissue wet wt (Fig. 1A). Significant reduc-
tions were also observed when ceramide values were expressed
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Fig. 1. Ceramide concentrations in mouse
renal cortex under control conditions, after
completing 45 minutes of ischemia (I), or after
45 minutes of ischemia ÷ 30 minutes of
reperfusion (IIR). The values are expressed per
mg of tissue wet wt (A) or per nmol of
phospholipid phosphate (B). Ischemia caused a
significant reduction in ceramide
concentrations. During reperfusion, ceramide
rebounded, reaching supra-normal
concentrations. [Not depicted, the post-ischemic
ceramide increases were also maintained (at
—175% of control values) after 60 minutes of
reflow, as discussed in the text].
either per total phospholipid phosphate (Fig. 1B) or per tissue dry
weight (control, 9.9 1.1; ischemia, 6.4 1.2 nmol/mg; P < 0.02;
not depicted).
Whole kidney reperfusion. After completing 30 minutes of
reperfusion, ceramide concentrations rebounded from the isch-
emic depressions, rising —40 to 80% above control concentrations
(Fig. 1). This was true whether the values were expressed per wet
wt (Fig. 1A), per phospholipid phosphate (Fig. 1B) or per tissue
dry weight (controls 8.4 0.8, vs. ischemia-reperfusion 15.3 1.1
nmol!mg dry wt; P < 0.0001; not depicted).
After completing 60 minutes of reflow (data not depicted), the
ceramide levels remained ——-75% higher than control values
(control 65 6, vs. reperfusion, 110 8 pmol/nmol phosphate;
P < 0.02; control, 8.8 1.0; vs. reperfusion, 14.3 1.4 nmol/mg
dry wt; P 0.03). This indicates relatively stable post-ischemic
ccramide elevations, theoretically permitting ceramide to impact
early reperfusion events.
PTS hypoxic injury. When hypoxic injury was induced in PTS, a
20 to 35% increase in ceramide levels was apparent, whether
expressed per mg PTS protein (Fig. 2A) or as PTS phospholipid
phosphate (Fig. 2B). This hypoxic challenge induced dramatic cell
injury, as denoted by 61 1% LDH release (vs. ii 1% for
controls).
Sphingosine concentrations during oxygen deprivation injury
By the completion of 45 minutes of in vivo ischemia (I),
sphingosine concentrations decreased by approximately 60% (Fig.
3A; P < 0.0001). When hypoxic injury was induced in PTS,
comparable sphingosine reductions were observed (Fig. 3B). The
latter change was associated with 54 3% LDH release (vs. 12
1% for controls).
During reperfusion (IIR) of in vivo ischemic kidneys, a prompt
increase in sphingosine occurred. This resulted in a normalization
of sphingosine concentrations whether expressed per tissue wet wt
(Fig. 3A) or dry weight (not depicted).
Sphingomyelin determinations
Despite the fact that ischemia-reperfusion increased ceramide
concentrations, no corresponding decrease in renal cortical sphiri-
gomyelin content resulted (controls 18.8 1.25 nmol/mg dry wt;
vs. ischemia/reperfusion 20.4 1.54). Simlarly, no decrease in
PTS sphingomyelin content was noted in post-hypoxic PTS
(0.10 0.003 vs. controls 0.10 0.004 nmol/nmol phosphate).
This was despite the fact that the post-hypoxic tubules manifested
63 2% LDH release (control oxygenated PTS 14 1%). The
failure to document a decrease in PTS sphingomyelin content was
not due to a parallel reduction in phospholipid phosphate since
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Fig. 2. Ceramide concentrations following
induction of hypoxic injury to isolated proximal
tubular segments (P1'S). The values were
expressed either as nmol/mg PTS protein (A) or
as pmoles/nmoles phospholipid phosphate (B).
In both instances, 20 minutes of hypoxia
produced —-20% ceramide increments
(simulating the change observed following in
vivo ischemic/reperfusion injury, as per Fig. 1).
The hypoxic challenge caused 61 1% LDH
release (11 1% for controls).
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Fig. 3. Sphingosine concentrations in renal
cortex (A) and in proximal tubule segments (B)
in response to 02 deprivation injury. In vivo
renal ischemia (I) caused > 50% declines in
sphingosine concentrations. These losses were
rapidly corrected during reperfusion (IIR), with
complete normalization of sphingosine levels
occurring within 30 minutes. The ability of 02
deprivation to deplete proximal tubular
sphingosine was confirmed in the PTS
experiments (—-50% sphingosine depressions
resulting with 20 mm of hypoxia). The hypoxic
challenge caused 54 3% LDH release (vs.
12 1% for controls).
Fig. 4. Sphingosine (A) and ceramide (B)
concentrations in normal PTS and in PTS
harvested from mice subjected to intramuscular
glycerol injection. PTS extracted from the
glycerol treated mice manifested markedly
depressed sphingosine concentrations after
completing a one hour in vitro incubation. In
contrast, ceramide concentrations did not
statistically differ from those observed in co-
incubated normal PTS preparations. The
glycerol PTS manifested 59 3% LDH release
by the end of the experiments (vs. 17 1% for
the controls). (That no ceramide increases were
observed despite this profound lethal cell injury
underscores that the ceramide increments
observed in the hypoxic PTS were not simply a
secondary manifestation of lethal cell injury).
the latter did not significantly change in response to hypoxic
damage (202 22 vs. 215 29 nmol phosphate/mg PTS protein;
post-hypoxic and oxygenated PTS, respectively).
Sphingosine/ceramide levels in response to in vivo/in vitro
myohemoglobinuric injury
PTS harvested from control and glycerol injected mice mani-
fested comparable % LDH release prior to the start of the one
hour experimental incubations (5 1% and 8 1%, respective-
ly). By completion of the in vitro incubations, the myohemoglobin
loaded PTS had sustained 59 3% LDH release, a result of iron
mediated oxidant stress [24, 25]. In contrast, the control PTS
manifested only 17 1% LDH release (P < 0.001).
By the end of the in vitro incubations, sphingosine concentra-
tions for the heme loaded PTS were depressed by —70%, com-
pared to control PTS values (Fig. 4A). However, no associated
change in ceramide concentrations resulted (Fig. 4B).
Effects of exogenous PLA2 on proximal tubule sphingosine and
ceramide expression
PLA2 treatment of PTS resulted in an approximate 50%
reduction in sphingosine concentrations (Fig. 5A). This was
quantitatively similar to the reductions seen with hypoxic and
heme protein-induced PTS injury. However, the PLA2-induced
sphingosine reductions occurred without any increase in cell death
(the PLA2 treated PTS and the control PTS each had 12 1%
LDH release). PLA2 treatment had no significant impact on PTS
ceramide concentrations (Fig. SB).
Figure 6 depicts the sphingosine levels in PTS challenged with
PLA2 in the absence or presence of dimethyisphingosine (DMS;
the sphingosine kinase inhibitor) or fumonisin Bi (FBi; the
ceramide synthase inhibitor). DMS did not alter sphingosine
levels under normal incubation conditions, and it did not attenu-
ate the PLA2-induced sphingosine depressions (suggesting that
PLA2 did not depress sphingosine levels by increasing its conver-
sion to sphingosine-1-phosphate). FBi almost doubled sphin-
gosine concentrations, compared to normal values (P < 0.01; Fig.
6), indicating that ceramide synthase is a critical determinant of
PTS sphingosine concentrations. However, FBi did not block the
PLA2-induced sphingosine depressions (strongly suggesting that
the reason for the PLA2-induced depression was not increased
sphingosine — ceramide conversion).
HK-2 cell experiments
Ceramide effect on ATP deplelion/Ca2 ionophore-induced cell
death. As shown in Figure 7A, neither cell permeant (C2) nor cell
impermeant (C16) ceramide increased LDH release in the ab-
sence of the ATP depletion/Ca2 ionophore challenge. When
control cells were challenged with ATP depletion/Ca2 ionophore
addition for one hour, only a mild increase in LDH release
occurred under normal culture conditions (6% increase over
control values; P = 0.001; Fig. 7B). However, when this challenge
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Fig. 6. Effect of sphingosine kinase inhibition (with dimethyisphin-
gosine, DMS) or ceramide synthase inhibition (with fumonisin Bi, FBi)
on PTS sphingosine levels in the presence or absence of PLA2. Under
normal incubation conditions, FBI treatment led to an approximate
doubling of sphingosine concentrations (*P < 0.01). Conversely, DMS did
not alter sphingosine levels. PLA2 induced —50% depressions in sphin-
gosine levels whether it was added in the presence or absence of DMS or
FBi. This suggests that PLA2 does not lower sphingosine by increasing its
flux via either of its two well defined metabolic pathways.
was conducted in the presence ofC2 ceramide, a 24% increase in
LDH release above control values resulted (P < 0.0001). In
contrast, C16 ceramide failed to alter the extent of ATP depletion!
Ca2 ionophore-induced LDH release.
Ceramide effect on PLA2 toxicity. Four hour exposures to PLA2
caused minimal cell lysis (LDH release) either in the presence or
absence of C2 ceramide or palmitic acid ( 14%; not depicted).
However, PLA2 treatment did cause sublethal injury, as evidenced
by an obvious shape change in the cells ("rounding up"), followed
by cell detachment from the culture plates. This process appeared
to be increased by ccramide but not palmitic acid treatment.
To quantitate the degree of cell detachment observed during
these experiments, the culture media (containing the detached
cells) were subjected to freeze thawing and sonication (causing
cell lysis) and % LDI-1 release was re-calculated (thereby provid-
Fig. 5. Effects of exogenous PLA2 on PTS
sphingosine and ceramide expression. Addition
of 5 U/mI of porcine pancreatic PLA2 caused
an approximate 50% decrease in PTS
sphingosine levels (A). The PLA2 challenge did
not alter % LDH release (12 1% with or
without PLA2), dissociating the sphingosine
decrements from lethal cell injury. In contrast
to the PLA2 effects on sphingosine, it had no
significant impact on PTS ceramide expression
(B).
ing an index of the % detached cells). As depicted in Figure 8,
whereas C2 ceramide caused no significant cell detachment on its
own, it essentially doubled the extent of cell detachment evoked
by PLA2. In contrast, the control lipid (palmitic acid; C16:0)
actually suppressed PLA2-induced cell detachment (P < 0.02),
suggesting that the C2 ceramide result was not simply a nonspe-
cific lipid effect. Thus, this experiment indicated that C2 ceramide
can impact on PLA2-induced toxicity (since cell detachment
presumably reflects a sublethal, or a pre-lethal, event).
Ceramide effects on arachidonic acid toxicity. As shown at the left
of Figure 9, addition of 50 M arachidonic acid (C20:4) to control
cells induced massive cell injury within a two hours period (85
3% LDH release). Approximately 80% of this injury was pre-
vented by C2 ceramide pre-treatment. Conversely, palmitic acid
(C16:0) induced only a slight cytoprotective effect (65 4% LDH
release with palmitate vs. 26 3% LDH release with C2
ceramide). As shown in the middle of Figure 9 (black bars),
neither test agent exerted an independent effect on LDH release
(that is, in the absence of arachidonic acid).
The comparison of C2 versus C16 ceramide effects on arachi-
donic acid toxicity are presented at the right of Figure 9. Unlike
C2 (cell permeable) ceramide, C16 ceramide, which has minimal
membrane permeability, exerted only a weak protective effect.
These data suggest that cell ceramide uptake is critical to its
ability to block arachidonic acid's cytotoxicity.
C2 ceramide addition to HK-2 cells did not appear to attenuate
3H-arachidonic acid accumulation by HK-2 cells (control cell
uptake, 690 45 cpm per well; ceramide treated cells, 745 62
cpm per well; N = 16 comparisons; NS). This suggests that
ceramide exerted a direct protective action, rather than simply
decreasing cellular arachidonate uptake.
DISCUSSION
It has been well documented that during the early stages of
ischemic renal injury, marked alterations in cellular phospholipid
homeostasis exist. The most characteristic changes noted to date
are: (1) the rapid accumulation of unesterified ("free") fatty acids
and lysophospholipids during ischemia (due to PLA2-induced
glycerophospholipid deacylation); (2) concomitant small reduc-
tions in total glycerophospholipid mass, most notably affecting
phosphatidylcholine; and (3) a rapid decline in the accumulated
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Fig. 8. Effect of C2 ceramide on the expression of PLA2 toxicity. As
discussed in the text, PLA2 the lipid challenges induced no lethal injury,
as assessed by LDH release. However, variable degrees of cell detachment
were observed, and this was quantitated by lysing the detached cells in the
medium. Thus, these derived % LDH release values (depicted in the
figure) reflected the extent of this detachment process. As shown at the
left of the figure, neither C2 ceramide nor the lipid control (C16:0,
palmitate) caused increased detachment. PLA2 caused —20% detach-
ment, and its extent was doubled in the presence of C2 ceramide. This was
presumably not just a non specific lipid effect, since the control lipid
(C16:0) actually decreased (P < 0.02), rather than increased, cell detach-
ment in the presence of PLA2.
fatty acid!lysophospholipid burden during early reperfusion, pre-
sumably due to metabolism [31, 44, 45]. While the overall
importance of these changes to the evolution of lethal cell injury
has been debated [31], there is no question that each of these
alterations can affect cell homeostasis. For example, free fatty
acids and lysophospholipids can exert direct membrane lytic
effects [44, 461; arachidonic acid accumulation negatively impacts
cellular energetics F47]; and alterations in membrane phospho-
lipid composition can alter the physical nature of the lipid bilayer,
and presumably, the function of the homeostatic proteins which
reside in it.
In contrast to an abundant literature documenting dramatic
Fig. 7. Effect of ceramides on the expression of
ATP depletion/Ca2 ionophore-mediated HK-2
cell injury. Neither C2 nor C16 ceramide
exposures x one hour under control conditions
altered LDH release (A). The ATP depletion
(antimycin/2-deoxyglucose)/Ca2 + ionophore
A23187 challenge iB) caused only a 6%
increase in LDH release above these control
values (*P < 0.01). However, when this
challenge was conducted in the presence of C2
ceramide, a marked increase in LDH release
resulted (that is, C2 ceramide worsened the
expression of ATP depletion/Ca2 ionophore-
initiated cell death). In contrast, C16 (cell
impermeant) ceramide had no effect on the
expression of ATP depletion/Ca2 ionophore
induced cell death.
fluxes in glycerophospholipid derivatives during ischemic injury,
to our knowledge, no previous studies have addressed whether
changes in sphingolipid metabolite expression also result. Since
sphingomyelin has been reported to be relatively well preserved
following renal ischemic!reperfusion injury [44, present data]
accumulation of sphingolipid breakdown products might seem
unexpected. However, the recent explosion of information con-
cerning the existence of a sphingomyelin (ceramide!sphingosine)
signaling cascade [1—4], plus the fact that sphingosine and cer-
amide levels might change independent of net sphingomyelin
breakdown (vide infra) prompted the present series of experi-
ments.
Indeed, the results of our studies clearly show that marked
alterations in both ceramide and sphingosine expression occur
during the evolution of renal tubular ischemic damage. When
whole kidneys were subjected to ischemia, essentially parallel
(—35 to 50%) reductions in renal cortical sphingosine and cer-
amide concentrations resulted. These did not reflect static
changes, since during 30 minutes of reperfusion, a dramatic
rebound in both sphingosine and ceramide concentrations oc-
curred. In the case of sphingosine, the post-ischemic increase
resulted in a return to control concentrations. However, ceramide
rebounded to —150 to 175% of normal values. Since these
increases were noted at both 30 and 60 minutes of reperfusion,
they theoretically were of sufficient duration to impact the evolu-
tion of reperfusion damage. It is noteworthy that these sphin-
gosine and ceramide changes (, with ischemia/ ' with reperfu-
sion) are opposite in direction to those which occur with free fatty
acids and lysophospholipids ( with ischemia! with reperfu-
sion). This indicates that fundamentally different mechanisms
must control the accumulation and disposal of glycerolipid and
sphingolipid breakdown products. That is, unlike the fatty acid!
lysophospholipid changes, the ceramide!sphingosine alterations
cannot simply be explained first by parent compound hydrolysis
and then subsequent metabolism of the generated catabolites.
One potential caveat of the above discussed cortical tissue
assessments is that the observed ceramide and sphingosine fluxes
might not have reflected proximal tubular cell events. This is
because of the heterogeneity of cell types within renal cortex,
making it impossible to conclude that perturbations in sphin-
gosine or ceramide concentrations existed within the proximal
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Fig. 9. Effects of C2 ceramide on the
expression of arachidonic acid (C20:4) toxicity
in HK-2 cells. When C20:4 was added to HK-2
cells under control conditions, —85% cell lysis
(LDH release) developed within two hours. C2
ceramide (10 mm pre-treatment + its presence
during the C20:4 challenge) almost completely
eliminated C20:4's lytic effect. In contrast,
palmitic acid (C16:0; the dominant saturated
fatty acid released during ischemic/hypoxic PTS
injury) had only a slight effect on the expression
of C20:4's cytotoxie effect (serving as a lipid
control for the C2 ceramide). Neither C2
ceramide nor C16:0 had an independent effect
on LDH release, as determined over the two
hours incubation period (•). As shown at the
right of the figure, C2 ceramide was far more
cytoprotective than was C16 ceramide. Since
C2, but not C16, ceramide penetrates cells,
these findings are consistent with cell uptake as
an important determinant of ceramide's ability
to mitigate C20:4 toxicity.
tubular epithelium. Since the latter is viewed by most investigators
as the critical target of ischemic renal damage, we sought confir-
mation that oxygen deprivation does, in fact, perturb sphingosine/
ceramide expression directly at the proximal tubular level. There-
fore, ceramide and sphingosine levels were studied during the
course of hypoxic injury in isolated PTS. After completing 20
minutes of hypoxia, sphingosine concentrations were depressed by
—50%. This strongly suggests that the sphingosine depressions
observed during in vivo ischemia reflected, at least in part, a
proximal tubular cell event. Unlike the renal cortical results,
ceramide levels slightly rose, rather than fell, during °2 depriva-
tion PTS injury (in a sense, recreating the ceramide increments
observed during early in vivo reperfusion). However, this differ-
ence in timing of the ceramide increments should not necessarily
be considered contradictory given inherent differences between in
vitro and in vivo proximal tubular damage. For example, during in
vitro hypoxic injury, cell death is predominantly expressed during
the oxygen deprivation period; in contrast, in vivo tubular cell
death is generally considered to be an early post-ischemic event
[48]. Thus, in both the in vivo and in vitro model systems, the
ceramide increases seemed to denote the lethal injury phase.
It is noteworthy that the employed hypoxic PTS challenge
induced —50 to 60% LDH release. This raises the possibility that
the observed alterations in sphingosine and ceramide expression
were merely secondary reflections of tubular cell death. For
example, dying cells might fail to maintain normal sphingosine
concentrations, and ceramide increments might simply reflect
nonspecific ceramide release from lethally damaged plasma mem-
branes. However, the available data argue against this view. First,
addition of exogenous PLA2 to PTS induced —50% sphingosine
depressions, but there was no corresponding loss of cell viability.
Second, tubules subjected to hypoxia or to myohemoglobin load-
ing manifested comparable degrees of lethal cell injury (—50 to
60% LDH release), and yet, only hypoxia caused ceramide
increments. Third, if the sphingosine depressions observed during
in vivo ischemia were simply due to lethal cell injury, a dramatic
recovery of sphingosine would not be expected during the early
reperfusion period. In sum, these observations indicate that the
altered sphingosine and ceramide levels were not simply second-
ary consequences of tubular cell death.
Although fluxes in both sphingosine and ceramide content
appear to be hallmarks of 02 deprivation-mediated tubular injury,
the triggers for these changes and the metabolic pathways through
which they are effected remain to be defined. These are highly
complex issues to resolve since alterations in synthesis, catabo-
lism, and metabolic conversion to alternative compounds might
each be involved. However, the available data suggest the follow-
ing: First, rapid reductions in sphingosine and ceramide during
renal ischemia must imply their consumption a concomitant
block in production. Whether metabolic conversion or simple
degradation of sphingosine and ceramide is involved remains
unknown. However, the failure of either DMS or fumonisin Bi to
preserve sphingosine content during PLA2-induced PTS injury
suggests that simple compound flux via the sphingosine kinase or
ceramide synthase pathway is probably not involved. Second, the
ischemic sphingosine and ceramide reductions probably do not
simply stem from a single metabolic event (such as, sphingomy-
elinase inhibition). This is suggested by the fact that the heme
loaded PTS and PLA2-exposed PTS demonstrated marked sphin-
gosine depressions in the absence of any corresponding reduction
in ceramide content. Third, PLA2 activation could be one stimulus
that initiates sphingosine depletion during ischemic tubular dam-
age. This is suggested by the fact that renal ischemia activates
PLA2 [29], and that PLA2 addition to PTS caused prompt
reductions in sphingosine content. (This new insight raises the
intriguing possibility that some of PLA2-induced signaling could
conceivably involve secondary sphingosine depletion); and
Fourth, post-ischemic increments in ceramide concentrations arc
not simply a result of sphingomyelin catabolism. This is because
no decrement in sphingomyelin content was observed in either the
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in vivo or the in vitro experiments. Thus, either increased sphin-
gomyelin turnover (parallel increases in production and hydroly-
sis), or breakdown of alternative ceramide containing molecules
(such as, glycosphingolipids) are seemingly involved. That PTS
ceramide levels slightly rose during hypoxia (when synthesis
should have been blocked) is consistent with the latter possibility.
Since ceramide concentrations were found to rise during early
reperfusion, the final goal of this study was to gain some support
for the concept that such increments could potentially contribute
to the evolution of renal tubular damage. Towards this end, the
impact of an increased cell ceramide burden on a well character-
ized model of ATP depIetion/Ca2 overload injury [43] was
assessed. When applied in a physiologically relevant and sublethal
dose, cell membrane permeable (C2) ceramide dramatically in-
creased the extent of ATP depletion/Ca2 ionophore-induced cell
death. That cell impermeant (C16) ceramide did not reproduce
this result suggests that cell ceramide uptake, and not simply
membrane contact, is required for this effect. We next questioned
whether ceramide might also affect cellular responses to PLA2-
and arachidonic acid-mediated attack. Although PLA2 induced no
lethal HK-2 cell injury (not surprising since it also failed to do so
in the PTS), sublethal damage did occur, as denoted by a
"rounding up" of the cells with subsequent detachment. Although
C2 ceramide alone induced no cell detachment, it doubled cell
detachment during PLA2 attack. In contrast, the palmitic acid
control slightly decreased PLA2-induced cell detachment, suggest-
ing that the ceramide effect was not simply a nonspecific lipid
effect. Finally, and most dramatically, C2 ceramide paradoxically
protected against arachidonic acid-mediated cytotoxicity, decreas-
ing LDH release from 85% to 26%. This could not simply be
explained by a block in HK-2 cell arachidonate uptake, since no
decrease in 3H arachidonic acid accumulation was noted. Further-
more, a nonspecific physical alteration of the arachidonic acid
challenge within the culture medium seems unlikely, since neither
C16 ceramide nor palmitic acid reproduced C2 ceramide's pro-
tective effect. Thus, it appears that cell ceramide insertion may
have stabilized the plasma membrane against arachidonic acid
attack. (In a sense, this protective action could potentially offset
some of ceramide's injury provoking effects, as noted above). In
sum, when these three sets of cell injury experiments are viewed
together, they support the hypothesis that cell ceramide content
may, in fact, modulate the expression of renal tubular damage.
Although these results remain largely "descriptive" at this time,
they nevertheless seem important: they provide a rationale for
further exploration of ceramide effects on acute renal tubular
injury and repair. That ceramide is known to trigger apoptosis
[1—5, 16—22], a well documented process within the post-ischemic
kidney [49, 50], provides an additional impetus for such investi-
gations.
In conclusion, the present studies provide the first evidence that
sphingosine and ceramide expression are markedly altered during
the induction stage of ischemic acute renal failure. During isch-
emia, —35 to 50% depressions in ceramide and sphingosine result.
Conversely, during reperfusion, sphingosinc and ceramide levels
rapidly rebound to either normal (sphingosine) or supranormal
(ceramide) levels. These fluxes occur independent of alterations
in total sphingomyelin content, suggesting that rates of sphingo-
myelin hydrolysis are not the prime, or only, determinant of these
changes. Since sphingosine and ceramide each exert potent and
diverse cell signaling effects, these newly documented changes
could have important implications for the induction and evolution
of post-ischemic acute renal failure. That PLA2, an important
determinant of ischemic injury, causes dramatic sphingosine
decrements, and that ceramide loading of cultured human prox-
imal tubular cells alters the severity of three different forms of
tubular injury (ATP depletion/Ca2 overload, PLA2 attack, and
arachidonate toxicity) strongly support this hypothesis. Given
these observations, further definition of sphingosine and ceramidc
effects on ischemic/reperfusion injury appear to be important
areas for future investigation.
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